DiaMedica Therapeutics Inc. Proceeds from Common Stock Issued
DiaMedica Therapeutics Inc. (DMAC) reported Proceeds from Common Stock Issued of $43.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-30
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $11.76M.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $31.53M.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for fiscal 2025 was $43.28M, a 268.45% increase from fiscal 2024.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for fiscal 2024 was $11.75M, a 68.12% decline from fiscal 2023.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for fiscal 2023 was $36.85M.
- DiaMedica Therapeutics Inc. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $11.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $43.28M derived: sum of 2 quarters · filed 2026-03-30 | $43.28M 10-K · filed 2026-03-30 | ||
| 2025-09-30 | $31.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $31.53M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $11.75M 10-K · filed 2026-03-30 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $11.75M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $11.75M 10-Q · filed 2025-08-12 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$4.00K derived: sum of 2 quarters · filed 2025-03-17 | $36.85M 10-K · filed 2025-03-17 | ||
| 2023-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $36.85M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $36.85M 10-Q · filed 2024-08-07 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | ||||
| 2021-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $29.85M derived: sum of 2 quarters · filed 2023-03-28 | $29.85M 10-K · filed 2023-03-28 | ||
| 2021-09-30 | $29.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $29.87M 10-Q · filed 2022-11-09 | |||
| 2021-09-26 | $30.00M 10-K · filed 2023-03-28 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-11 | ||||
| 2020-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $21.12M derived: sum of 2 quarters · filed 2022-03-14 | $21.12M derived: sum of 3 quarters · filed 2022-03-14 | $28.80M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $21.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $21.19M derived: sum of 2 quarters · filed 2021-11-10 | $28.87M 10-Q · filed 2021-11-10 | ||
| 2020-08-10 | $23.00M 10-K · filed 2022-03-14 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $7.68M 10-Q · filed 2021-08-11 | |||
| 2020-04-10 | $23.00M 10-Q · filed 2021-11-10 | ||||
| 2020-03-31 | $7.68M 10-Q · filed 2021-05-05 | ||||
| 2020-02-13 | $8.50M 10-K · filed 2022-03-14 | ||||
| 2018-12-31 | $14.73M 10-K · filed 2020-03-23 | ||||
| 2017-12-31 | $2.92M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |